The data underlying the results presented in the study are available in the Supplemental Materials along with the data used to generate the results.

Introduction {#sec001}
============

Pulmonary alveolar proteinosis (PAP) is a rare syndrome comprising a heterogeneous group of diseases characterized by the accumulation of pulmonary surfactant in alveolar macrophages and the alveolar space \[[@pone.0213179.ref001], [@pone.0213179.ref002]\]. Eventually, surfactant accumulation results in respiratory impairment and/or failure as well as an increased risk of opportunistic infections \[[@pone.0213179.ref003]\]. This syndrome occurs in individuals from ages 8 to 90 years, but it is most common in male smokers in the third to fourth decade \[[@pone.0213179.ref004], [@pone.0213179.ref005]\]. The catabolism of pulmonary surfactant in alveolar macrophages is controlled by granulocyte-macrophage-colony stimulating factor (GM-CSF) \[[@pone.0213179.ref006]\]. GM-CSF is a cytokine that modulates the survival, differentiation, proliferation, and priming of myeloid cells \[[@pone.0213179.ref007]\]. GM-CSF signaling can be disrupted by mutations in the GM-CSF gene \[[@pone.0213179.ref008], [@pone.0213179.ref009]\] or its receptors \[[@pone.0213179.ref010]--[@pone.0213179.ref013]\], as well as by neutralizing autoantibodies \[[@pone.0213179.ref002], [@pone.0213179.ref014], [@pone.0213179.ref015]\]. In this regard, autoimmune PAP is the disease that results from autoantibodies directed against GM-CSF, and the identification of neutralizing, polyclonal anti-GM-CSF autoantibodies in autoimmune PAP is an essential component of the disease diagnosis.

In most autoimmune diseases, CD4^+^ T cells are required to assist B cells in isotype switching, which is necessary for the generation of autoantibodies such as those found in autoimmune PAP patients. Few studies have investigated the role of the adaptive immune response, and no studies to date have investigated the association between the genetic susceptibility to autoimmune PAP and *HLA*. In the vast majority of immune-mediated diseases, genetic susceptibility has been most strongly associated with the *HLA* region on the short arm of chromosome 6 \[[@pone.0213179.ref016]\]. For example, the major genetic contribution to rheumatoid arthritis (RA) involves *DRB1* alleles such as *DRB1\*04*:*01* and *\*04*:*04* \[[@pone.0213179.ref017]\], whereas *HLA-DQ* alleles, especially *DQB1*:*02*:*01* and *DQB1*:*03*:*02*, provide the major genetic contribution to type 1 diabetes (T1D) \[[@pone.0213179.ref016]\]. In the case of chronic beryllium disease, genetic susceptibility is strongly linked to *HLA-DPB1* alleles possessing a glutamic acid at position 69 of the β-chain \[[@pone.0213179.ref018]\]. Thus, the impetus for this study was to identify to *HLA* alleles that confer susceptibility to the generation of autoimmune PAP.

Methods {#sec002}
=======

Patients and controls {#sec003}
---------------------

We collected DNA from 41 Caucasian subjects with autoimmune PAP defined by a serum level of GM-CSF autoantibody greater than 5.6 μg/mL. These patients were recruited from the Translational Pulmonary Science Center (TPSC) at Cincinnati Children's Hospital Medical Center (CCHMC), the University of Cincinnati Medical Center, and other Rare Lung Disease Network (RLDN) centers/affiliates. The Cincinnati Children\'s Hospital Medical Center Office of Research Compliance and Regulatory Affairs issued for this study IRB \# 2011--0147. Written consent was obtained from all patients enrolled in the study. The patients were all Caucasians with a positive GM-CSF autoantibody test \[[@pone.0213179.ref019]\], with a mean age of 44.3+/-6.7 years (+/-SEM), and comprised of 40.9% female and 59.1% male, from various regions in the United States (84.1%), Canada (2.3%), Turkey (13.6%) Subjects and demographic information are available in [S1 Table](#pone.0213179.s001){ref-type="supplementary-material"}.

High resolution molecular typing for *HLA-A*, *B*, *C*, *DRB1*, *DPB1*, *DQB1*, *DRB3*, *DRB4* and *DRB5* was performed at ClinImmune Laboratories at the University of Colorado Anschutz Medical Campus. 1,000 control subjects for *HLA* analysis were acquired from the National Marrow Donor Program (NMDP) Full HLA types for patients and controls are published in [S2 Table](#pone.0213179.s002){ref-type="supplementary-material"}. For validation of small sample sizes in HLA Epitope Analysis Program (HEAP), we used data from patients with RA (patient data from IHWG) and T1D (data from the T1D Genetics Consortium).

HLA analysis and statistics {#sec004}
---------------------------

The number of patients carrying at least one copy of each allele was counted and compared with the number of controls carrying at least one copy of the same allele. The significance of each was calculated using a Chi-square test or Fisher's exact test as appropriate depending on the number of subjects in each contingency table. The resulting p-values were corrected for multiple comparisons using the false discovery rate method \[[@pone.0213179.ref020]\]. We additionally performed an equivalence test for all alleles using R software version 3.4.4 and the package TOSTER (<https://cran.r-project.org/web/packages/TOSTER/index.html>).

HLA amino acid association analysis was performed using the R software package version 2.6.1. Combinations of 1--4 polymorphic amino acids at positions 8--93 of HLA-DRB1, DPB1 and DQB1, as well as combinations of up to 4 amino acids at positions 2--192 of HLA-A, B and C were analyzed for association with PAP. Chi-square or Fisher's exact tests were calculated as appropriate, and the P-values were adjusted for multiple comparisons.

HEAP validation for small sample sizes {#sec005}
--------------------------------------

In small sample sizes, allele association studies are likely to miss true positive associations due to polymorphisms in the *HLA* region. Rare alleles that may be truly disease susceptible alleles cannot reach statistical significance due to their low frequency in both patient and control groups. Amino acid association tests, on the other hand, benefit small studies by identifying shared features between disparate alleles, including rare alleles.

To test whether we could detect a true positive HLA association with small patient numbers, we analyzed known HLA amino acid associations from RA and T1D. RA is strongly associated with alleles of *DRB1\*04*, which in single amino acid analysis can be identified by the presence of histidine at position 13 \[[@pone.0213179.ref020]\]. T1D has strong single amino acid associations in both HLA-DRB1 (histidine at position 13) and HLA-DQB1 (alanine at position 57) \[[@pone.0213179.ref021]\]. In T1D, the DQB1 association is stronger than the association in DRB1 \[[@pone.0213179.ref021]\]. We determined whether we could correctly identify the known HLA amino acid associations in RA and T1D through random sampling of 50, 40, 30 and 20 patients. We performed each random sampling ten times for each level of patient numbers and with 1,000 NMDP controls each. With these data, we determined how frequently HEAP could identify the known amino acid association for RA and T1D. Statistics were performed as described above for PAP association.

Results {#sec006}
=======

*HLA* Allele frequency and amino acid polymorphism in autoimmune PAP {#sec007}
--------------------------------------------------------------------

We collected DNA from 47 Caucasian patients with autoimmune PAP from Cincinnati Children's Medical Center as part of the RLDN. We performed high resolution typing of all classical loci of HLA class I and class II. We analyzed both allele frequencies and amino acid frequencies between patients and 1000 ethnic-matched controls provided by the NMDP. To identify potential shared amino acid sequences, we used HEAP, which compares all polymorphic amino acids in a locus \[[@pone.0213179.ref021]--[@pone.0213179.ref023]\]. We examined potential HLA shared amino acids from 1 to 4 non-contiguous amino acids and analyzed a total of 5,699,818 possible amino acid combinations. However, we did not find any significant associations at the amino acid level ([S9](#pone.0213179.s009){ref-type="supplementary-material"}--[S32](#pone.0213179.s032){ref-type="supplementary-material"} Tables). We also calculated allele frequencies for all loci and performed a chi-square analysis between patients and controls. In our control and patient populations, we identified 203 different alleles in *HLA-A*, *B*, *C*, *DRB1*, *DPB1* and *DQB1* (Tables [1](#pone.0213179.t001){ref-type="table"}--[6](#pone.0213179.t006){ref-type="table"}), and none were significantly associated with autoimmune PAP. Many of the alleles tested were rare (\<1% in both patient and control groups) and were not found to be associated with PAP. For full allele results, see [S3](#pone.0213179.s003){ref-type="supplementary-material"}--[S8](#pone.0213179.s008){ref-type="supplementary-material"} Tables.

10.1371/journal.pone.0213179.t001

###### HLA-A alleles in patients and controls.

![](pone.0213179.t001){#pone.0213179.t001g}

  Allele   Patients (%)   Controls (%)   p---value   p---adjusted
  -------- -------------- -------------- ----------- --------------
  01:01    9 (30.0)       281 (28.1)     0.84        1
  02:01    12 (40.0)      487 (48.7)     0.35        1
  02:05    1 (3.3)        16 (1.6)       0.40        1
  02:06    1 (3.3)        1 (0.1)        0.06        1
  03:01    9 (30.0)       282 (28.2)     0.84        1
  11:01    3 (10.0)       112 (11.2)     1           1
  23:01    1 (3.3)        45 (4.5)       1           1
  24:02    6 (20.0)       155 (15.5)     0.45        1
  25:01    2 (6.7)        44 (4.4)       0.39        1
  26:01    3 (10.0)       61 (6.1)       0.43        1
  29:01    1 (3.3)        10 (1.0)       0.28        1
  29:02    5 (16.7)       60 (6.0)       0.04        1
  30:01    0 (0.0)        33 (3.3)       0.62        1
  30:02    2 (6.7)        12 (1.2)       0.06        1
  31:01    0 (0.0)        47 (4.7)       0.39        1
  32:01    1 (3.3)        73 (7.3)       0.72        1
  33:01    0 (0.0)        17 (1.7)       1           1
  68:01    1 (3.3)        53 (5.3)       1           1
  68:02    1 (3.3)        14 (1.4)       0.36        1

10.1371/journal.pone.0213179.t002

###### HLA-B alleles in patients and controls.

![](pone.0213179.t002){#pone.0213179.t002g}

  Allele   Patients (%)   Controls (%)   *p*---value   *p*---adjusted
  -------- -------------- -------------- ------------- ----------------
  07:02    10 (33.3)      264 (26.4)     0.40          1
  07:05    1 (3.3)        4 (0.4)        0.14          1
  08:01    6 (20.0)       190 (19.0)     0.82          1
  13:02    0 (0.0)        65 (6.5)       0.25          1
  14:01    1 (3.3)        14 (1.4)       0.36          1
  14:02    2 (6.7)        41 (4.1)       0.36          1
  15:01    3 (10.0)       118 (11.8)     1             1
  18:01    2 (6.7)        84 (8.4)       1             1
  27:02    0 (0.0)        18 (1.8)       1             1
  27:05    2 (6.7)        65 (6.5)       1             1
  35:01    4 (13.3)       133 (13.3)     1             1
  35:02    1 (3.3)        20 (2.0)       0.47          1
  35:03    2 (6.7)        30 (3.0)       0.24          1
  35:08    1 (3.3)        6 (0.6)        0.19          1
  37:01    2 (6.7)        20 (2.0)       0.13          1
  38:01    1 (3.3)        33 (3.3)       1             1
  39:01    0 (0.0)        34 (3.4)       0.62          1
  40:01    2 (6.7)        88 (8.8)       1             1
  40:02    0 (0.0)        22 (2.2)       1             1
  44:02    3 (10.0)       173 (17.3)     0.46          1
  44:03    6 (20.0)       105 (10.5)     0.13          1
  44:05    1 (3.3)        12 (1.2)       0.32          1
  49:01    1 (3.3)        44 (4.4)       1             1
  50:01    2 (6.7)        20 (2.0)       0.13          1
  51:01    1 (3.3)        85 (8.5)       0.51          1
  51:08    1 (3.3)        4 (0.4)        0.14          1
  52:01    2 (6.7)        23 (2.3)       0.16          1
  55:01    1 (3.3)        42 (4.2)       1             1
  56:01    0 (0.0)        14 (1.4)       1             1
  57:01    2 (6.7)        78 (7.8)       1             1
  58:01    0 (0.0)        15 (1.5)       1             1

10.1371/journal.pone.0213179.t003

###### HLA-C alleles in patients and controls.

![](pone.0213179.t003){#pone.0213179.t003g}

  Allele   Patients (%)   Controls (%)   *p*---value   *p*---adjusted
  -------- -------------- -------------- ------------- ----------------
  01:02    3 (10.0)       6 (6.0)        0.45          1
  02:02    1 (3.3)        9.7 (9.7)      0.36          1
  03:03    6 (20.0)       10.4 (10.4)    0.15          1
  03:04    4 (13.3)       13.4 (13.4)    1             1
  04:01    8 (26.7)       22.7 (22.7)    0.83          1
  05:01    4 (13.3)       16.3 (16.3)    0.64          1
  06:02    4 (13.3)       18.9 (18.9)    0.49          1
  07:01    7 (23.3)       27.6 (27.6)    0.55          1
  07:02    13 (43.3)      27.9 (27.9)    0.17          1
  07:04    0 (0.0)        3 (3.0)        0.62          1
  08:02    3 (10.0)       5.4 (5.4)      0.42          1
  12:02    1 (3.3)        2.2 (2.2)      0.53          1
  12:03    3 (10.0)       9.8 (9.8)      1             1
  14:02    0 (0.0)        2.4 (2.4)      1             1
  15:02    0 (0.0)        4.4 (4.4)      0.39          1
  15:05    1 (3.3)        0.5 (0.5)      0.18          1
  16:01    4 (13.3)       6.4 (6.4)      0.27          1
  16:02    1 (3.3)        0.9 (0.9)      0.28          1
  16:04    1 (3.3)        0.3 (0.3)      0.12          1
  17:01    0 (0.0)        1.5 (1.5)      1             1

10.1371/journal.pone.0213179.t004

###### HLA-DRB1 alleles in patients and controls.

![](pone.0213179.t004){#pone.0213179.t004g}

  Allele   Patients (%)   Controls (%)   p---value   p---adjusted
  -------- -------------- -------------- ----------- --------------
  01:01    7 (17.9)       169 (16.9)     0.83        1
  01:02    1 (2.6)        21 (2.1)       0.57        1
  01:03    0 (0.0)        16 (1.6)       1           1
  03:01    4 (10.3)       210 (21.0)     0.15        1
  04:01    1 (2.6)        153 (15.3)     0.02        1
  04:02    2 (5.1)        20 (2.0)       0.20        1
  04:03    1 (2.6)        15 (1.5)       0.46        1
  04:04    0 (0.0)        60 (6.0)       0.16        1
  04:05    0 (0.0)        10 (1.0)       1           1
  04:07    1 (2.6)        12 (1.2)       0.39        1
  07:01    14 (35.9)      260 (26.0)     0.17        1
  08:01    2 (5.1)        50 (5.0)       1           1
  08:02    1 (2.6)        2 (0.2)        0.11        1
  08:03    1 (2.6)        5 (0.5)        0.21        1
  09:01    0 (0.0)        15 (1.5)       1           1
  10:01    4 (10.3)       12 (1.2)       0.00        0.36
  11:01    4 (10.3)       128 (12.8)     0.81        1
  11:02    1 (2.6)        8 (0.8)        0.29        1
  11:03    3 (7.7)        21 (2.1)       0.06        1
  11:04    4 (10.3)       57 (5.7)       0.28        1
  12:01    0 (0.0)        28 (2.8)       0.62        1
  13:01    3 (7.7)        138 (13.8)     0.35        1
  13:02    4 (10.3)       88 (8.8)       0.77        1
  13:03    1 (2.6)        19 (1.9)       0.54        1
  14:01    3 (7.7)        53 (5.3)       0.46        1
  14:06    1 (2.6)        0 (0.0)        0.04        1
  15:01    11 (28.2)      269 (26.9)     0.86        1
  15:02    0 (0.0)        19 (1.9)       1           1
  16:01    2 (5.1)        40 (4.0)       0.67        1

10.1371/journal.pone.0213179.t005

###### HLA-DPB1 alleles in patients and controls.

![](pone.0213179.t005){#pone.0213179.t005g}

  Allele   Patients (%)   Controls (%)   p---value   p---adjusted
  -------- -------------- -------------- ----------- --------------
  01:01    6 (15.0)       99 (9.9)       0.28        1
  02:01    8 (20.0)       261 (26.1)     0.39        1
  02:02    1 (2.5)        11 (1.1)       0.38        1
  03:01    6 (15.0)       206 (20.6)     0.55        1
  04:01    21 (52.5)      675 (67.5)     0.05        1
  04:02    17 (42.5)      227 (22.7)     0.01        0.71
  05:01    2 (5.0)        27 (2.7)       0.31        1
  06:01    1 (2.5)        41 (4.1)       1           1
  09:01    1 (2.5)        10 (1.0)       0.35        1
  10:01    1 (2.5)        29 (2.9)       1           1
  11:01    3 (7.5)        30 (3.0)       0.13        1
  13:01    1 (2.5)        36 (3.6)       1           1
  14:01    3 (7.5)        24 (2.4)       0.08        1
  15:01    0 (0.0)        11 (1.1)       1           1
  16:01    0 (0.0)        14 (1.4)       1           1
  17:01    1 (2.5)        31 (3.1)       1           1
  19:01    1 (2.5)        18 (1.8)       0.53        1
  23:01    0 (0.0)        15 (1.5)       1           1

10.1371/journal.pone.0213179.t006

###### HLA-DQB1 alleles in patients and controls.

![](pone.0213179.t006){#pone.0213179.t006g}

  Allele   Patients (%)   Controls (%)   *p*---value   *p*---adjusted
  -------- -------------- -------------- ------------- ----------------
  02:01    4 (10.0)       381 (38.1)     0.47          1
  03:01    13 (32.5)      343 (34.3)     0.81          1
  03:02    5 (12.5)       167 (16.7)     0.66          1
  03:03    6 (15.0)       91 (9.1)       0.26          1
  04:02    4 (10.0)       60 (6.0)       0.30          1
  05:01    12 (30.0)      210 (21.0)     0.17          1
  05:02    2 (5.0)        47 (4.7)       0.71          1
  05:03    3 (7.5)        53 (5.3)       0.47          1
  06:01    0 (0.0)        20 (2.0)       1             1
  06:02    12 (30.0)      267 (26.7)     0.64          1
  06:03    3 (7.5)        140 (14.0)     0.35          1
  06:04    5 (12.5)       82 (8.2)       0.37          1
  06:09    0 (0.0)        11 (1.1)       1             1

*DRB3*, *DRB4* and *DRB5* are three protein-coding loci in tight linkage disequilibrium with *DRB1*. These alleles pair with DRα, are expressed on the cell surface, and present peptides to T cells as any other class II allele. We imputed these alleles based on linkage analysis and examined the frequencies of these loci for potential association with PAP; however, no associations were identified ([Table 7](#pone.0213179.t007){ref-type="table"}). Collectively, with our cohort, our data show that autoimmune PAP is unlikely to have an *HLA* association that can explain disease development.

10.1371/journal.pone.0213179.t007

###### Alleles in linkage with DRB1 in patients and controls.

![](pone.0213179.t007){#pone.0213179.t007g}

  Allele   Patients (%)   Controls (%)   *p*---value   Odds Ratio
  -------- -------------- -------------- ------------- ------------
  DRB3     25 (60.1)      632 (63.2)     0.869         0.91
  DRB4     20 (48.7)      496 (49.6)     0.874         1.07
  DRB5     10 (24.4)      324 (32.4)     0.311         0.67

Based on DRB1 types we determined the presence of a DR locus in linkage disequilibrium with DRB1 that may also contribute to disease. We calculated the odds-ratio for each additional locus and performed a chi-square analysis.

Given the small sample size, we performed a test of equivalence. In traditional t-tests, the null hypothesis is that the means in two groups are not different. Our initial analysis suggested that we cannot reject this null hypothesis. However, this does not demonstrate unequivocally that the groups are the same. In an equivalence test, the null hypothesis is that the two groups are different. A significant p-value in an equivalence test would allow us to reject this null hypothesis and indicates that the means between our two groups are equivalent. An equivalence test was performed for all alleles, and for each one we obtain a highly significant p-value, suggesting that there is no difference between the frequencies of *HLA* alleles between patients and controls. The maximum p-value we observed over all alleles tested was 4.23 x 10^−12^.

Adequacy of sample size {#sec008}
-----------------------

Due to the small number of autoimmune PAP subjects enrolled in the present study, we queried whether an association between HLA and similar numbers of subjects with diseases of known HLA associations (e.g., T1D and RA) could be detected. As shown in [Fig 1](#pone.0213179.g001){ref-type="fig"}, we found that HEAP could consistently identify a strong HLA association with as few as 20 patients in both T1D and RA. Thus, our findings suggest that our sample size of 47 should be adequate to detect an HLA association in autoimmune PAP, if a strong association exists.

![HEAP limits of detection by patient number.\
Identification of significant p-values with known disease associated epitopes by number of patients in the sample. Y-axis shows--Log(p-value) from the epitope analysis, X-axis shows the number of patient samples included in each analysis. For highly significant HLA associations, HEAP can consistently identify association with as few as 20 patients.](pone.0213179.g001){#pone.0213179.g001}

Discussion {#sec009}
==========

Based on the autoimmune nature of PAP, we hypothesized that a link existed between this disease and *HLA*. However, our study suggests that no such link exists. It remains possible that the lack of an association was due to the small sample size (47 patients). However, we did not note any trends towards association. As discussed above, our sample size should be sufficient to identify a strong positive association. However, it may not be large enough to definitively conclude the absence of an association. Previous studies in our laboratory have conclusively demonstrated the lack of an *HLA* association with as few as 150 patients \[[@pone.0213179.ref022]\]. However, it should be noted that our methodology can identify a strong positive *HLA* association with only 50 patients \[[@pone.0213179.ref021]\]. Our HEAP analysis consistently identified a strong, single amino acid HLA association in T1D and RA with as few as 20 subjects. Collectively, these data suggest that our sample size should be capable of detecting an association if one were present. However, due to sample size considerations, we were forced to limit our study to Caucasian patients. A larger study with a more diverse population would allow a more conclusive assessment and to include other ethnic minorities who represent more diverse *HLA* alleles.

*HLA*-linked autoimmune diseases generally have a T cell-mediated component. Our initial hypothesis was based on the finding of an increased number of CD4^+^ and CD8^+^ T cells in the bronchoalveolar lavage of patients with PAP \[[@pone.0213179.ref024]\]. This suggests HLA involvement in presenting self-antigen to T cells which may then lead to CD4^+^ T cells helping B cells to class-switch. This would be consistent with our observations that antibodies against GM-CSF in autoimmune PAP patients are IgG \[[@pone.0213179.ref014]\]. However, it is possible that the increased number of T cells observed in the lungs of PAP patients was secondary to infection and can still account for the class-switched antibodies against GM-CSF. The absence of an *HLA* association in this cohort of autoimmune PAP subjects raises the possibility that the T cell alveolitis may be a direct consequence of pulmonary infection.

Despite being found predominantly in patients with autoimmune PAP, anti-GM-CSF antibodies are also found in the serum of healthy subjects. It is not entirely unusual to observe autoantibodies in healthy individuals and suggests that the progression to disease state involves interactions between specific genes and the environment. In this case, it is possible that autoantibodies directed against GM-CSF function in normal, healthy individuals to prevent excessive inflammatory responses; thus, protecting the lung from damage. Genetically susceptible individuals would have difficulty controlling the amount of anti-GM-CSF antibodies. In this regard, it is possible that autoimmune PAP represents an improper control of anti-GM-CSF antibodies. autoimmune PAP patients may have a genetic link that makes them more susceptible to lung infection but unfortunately, in this study, no link between *HLA* and autoimmune PAP was identified.
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